Clinical Trial

Role of the Fibroblast Activation Protein (FAP) as Biomarker of Fibrotic Lung Diseases

Name: Role of the Fibroblast Activation Protein (FAP) as Biomarker of Fibrotic Lung Diseases — clinical trial record (NCT06189820)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Study acronym: FAPIPET

Recruiting Phase 2

View on ClinicalTrials.gov →

Summary

To evaluate the effect of an anti-fibrotic treatment initiation on the fibrotic activity as assessed by FAPI PET/CT.

Trial Details

NCT Number	NCT06189820
Lead Sponsor	Erasme University Hospital
Conditions	Pulmonary Fibrosis, Lung Fibrosis, Idiopathic Pulmonary Fibrosis, FAP
Enrollment	70 participants
Start Date	2023-03-09
Primary Completion	2027-03-09 (estimated)
Study Completion	2027-03-09 (estimated)
Updated on ClinicalTrials.gov	2024-01-05